Loescher leaving Merck to take Siemens CEO job

Share this article:
Merck announced that its president of global human health, Peter Loescher, plans to leave the company this summer to become CEO of German electrical engineering firm and electronics manufacturer Siemens. Austria-born Loescher, whose duties at Merck will end July 1, was hired just last year by the Whitehouse Station, NJ, drugmaker. He announced his resignation on Sunday morning following a meeting of Siemens’ supervisory board in Munich, Germany, where the company named him as its CEO. Loescher’s responsibilities at Merck included the management of more than 35,000 employees. He was given direct responsibility for Merck’s marketing and sales divisions around the world. He also oversaw marketing for Merck’s increasingly important vaccines business. Loescher worked for more than 10 years at Germany's Hoechst AG, now part of Sanofi-Aventis, before joining UK medical-diagnostics firm Amersham in 2002. He then joined the corporate executive council of General Electric after the company acquired Amersham in 2004 before joining Merck in May 2006. Loescher had been viewed as a potential successor to Merck CEO Richard Clark. Clark said Merck remained committed to the goals of the global human health organization. “We continue to be pleased with the strong business performance across all the global human health franchises and regions, and we are confident that it will continue,” Clark said in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...